These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27265777)

  • 1. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence.
    Georgianos PI; Vaios V; Eleftheriadis T; Zebekakis P; Liakopoulos V
    Curr Vasc Pharmacol; 2017; 15(6):599-606. PubMed ID: 28155610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D
    Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
    Elshahat A; Mansour A; Ellabban M; Diaa A; Hassan A; Fawzy A; Saad OA; Abouelmagd M; Eid M; Elaraby A; Elkasaby MH; Abdelaziz A
    BMC Cardiovasc Disord; 2024 Sep; 24(1):489. PubMed ID: 39271992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.
    Chen KT; Kang YN; Lin YC; Tsai IL; Chang WC; Fang TC; Wu MS; Kao CC
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):916-925. PubMed ID: 34117083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.
    Baker WL; White WB
    Ann Pharmacother; 2012 Jun; 46(6):889-94. PubMed ID: 22669801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis.
    Zhu Y; Liu Y; Cai R; Zheng D; Liang X; Tao M; Jin J; Li Y; He Q
    Medicine (Baltimore); 2021 Feb; 100(8):e24882. PubMed ID: 33663116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.
    Lu R; Zhang Y; Zhu X; Fan Z; Zhu S; Cui M; Zhang Y; Tang F
    Int Urol Nephrol; 2016 Sep; 48(9):1499-509. PubMed ID: 27193436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis.
    Zhao Y; Yan B; Zhao Z; Wang S; Weng X
    Ren Fail; 2016; 38(4):589-99. PubMed ID: 26905224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
    Bomback AS
    Blood Purif; 2016; 41(1-3):166-70. PubMed ID: 26765793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure.
    Kobayashi M; Yamashina A; Satomi K; Tezuka A; Ito S; Asakura M; Kitakaze M; Ferreira JP
    Int J Cardiol; 2024 Nov; 415():132477. PubMed ID: 39181408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
    Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
    Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.